ReviewTherapeutic advances in neurological disorders2018
Treatment of glioblastoma in adults.
Review in Therapeutic advances in neurological disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.International journal of molecular sciences · 2019Pooled it
- Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma.Frontiers in immunology · 2020Trial
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.Nature medicine · 2019Trial
- Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.Biochemical pharmacology · 2026Review
- Regrowth Patterns in Glioblastoma-Survival and Predictors.Cancer medicine · 2026Article
- Functional implications of atypical action potential generation in the (patho)physiological brain: from developmental program to glioma.Frontiers in neural circuits · 2026Review
- CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma.Mathematical biosciences · 2025Article
- Go-or-grow models in biology: a monster on a leash.Journal of mathematical biology · 2025Review
- Microtubule-Targeting Agents: Advances in Tubulin Binding and Small Molecule Therapy for Gliomas and Neurodegenerative Diseases.International journal of molecular sciences · 2025Review
- Combined peritumoral radiomics and clinical features predict 12-month progression free survival in glioblastoma.Journal of neuro-oncology · 2025Article
- Prognostic modeling of glioma using epilepsy-related genes highlights PAX3 as a regulator of migration and vorinostat sensitivity.Frontiers in neurology · 2025Article
- Risk factors and a new nomogram for glioblastoma: based on a retrospective study.Frontiers in immunology · 2025Article
- Modality redundancy for MRI-based glioblastoma segmentation.International journal of computer assisted radiology and surgery · 2024Article
- Machine learning predicts cuproptosis-related lncRNAs and survival in glioma patients.Scientific reports · 2024Article
- Deep intravital brain tumor imaging enabled by tailored three-photon microscopy and analysis.Nature communications · 2024Article
- A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.Brain and behavior · 2024Article
- USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.CNS neuroscience & therapeutics · 2024Article
- Whole-body fluorescence cryotomography identifies a fast-acting, high-contrast, durable contrast agent for fluorescence-guided surgery.Theranostics · 2024Article
- Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- SNORD17-mediated KAT6B mRNA 2'-O-methylation regulates vasculogenic mimicry in glioblastoma cells.Cell biology and toxicology · 2023Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of a glioblastoma is mainly made on the basis of their microscopic appearance with the additional determination of epigenetic as well as mutational analyses as deemed appropriate and taken into account in different centers. How far the recent discovery of tumor networks will stimulate novel treatments is a subject of intensive research. A tissue diagnosis is the mainstay. Regardless of age, patients should undergo a maximal safe resection. Magnetic resonance imaging is the surrogate parameter of choice for follow up. Patients should receive chemoradiotherapy with temozolomide with the radiation schedule adapted to performance status, age and tumor location. The use of temozolomide may be reconsidered according to methylguanine DNA methyltransferase
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.